Medical news today: Wednesday, November 11, 2026
FDA approves pimicotinib; GLP-1 eye warning and two device alerts; WHO updates TB resistance catalogue
Get tomorrow's issue in your inbox.
- 01
FDA approves pimicotinib for adults with symptomatic tenosynovial giant cell tumor
Source: U.S. Food and Drug Administration
On November 10, 2026, the FDA approved pimicotinib (Pimjetmi) for adults with symptomatic tenosynovial giant cell tumor when surgical resection may worsen functional limitation or cause severe morbidity. In the randomized, placebo-controlled phase 3 MANEUVER trial, the week-25 objective response rate was 56% with pimicotinib versus 3.2% with placebo; median duration of response was not reached. The FDA lists pruritus, rash, facial or periorbital edema, fatigue, nausea, headache and peripheral edema among common adverse reactions, with warnings for hepatotoxicity, embryo-fetal toxicity and increased serum creatinine.
Why it mattersThis is a new U.S. regulatory approval for a defined adult TGCT population in which surgery may be disabling. Pharmacovigilance teams should review the approved label and its hepatic, reproductive and laboratory warnings; the trial result should not be generalized to all TGCT or to patients who are suitable for surgery. More on Approvals & regulatory →
- 02
Two phase 3 trials find retatrutide reduced knee pain and body weight in adults with obesity
Source: New England Journal of Medicine
The New England Journal of Medicine published results on November 8 from two randomized, double-blind, placebo-controlled phase 3 trials of once-weekly retatrutide in adults without diabetes who had painful knee osteoarthritis and a BMI of at least 27. TRIUMPH-4 enrolled 445 participants and assessed outcomes at 68 weeks; TRIUMPH-1-OA enrolled 574 and assessed knee pain at 80 weeks. Retatrutide reduced WOMAC pain scores more than placebo in both trials. In TRIUMPH-4, mean body-weight change was −20.0% with 9 mg and −23.7% with 12 mg, versus −4.6% with placebo. Serious adverse events were more common with retatrutide than placebo, and gastrointestinal events were the most common adverse events. The trials were funded by Eli Lilly. Retatrutide remains investigational and is not an approved treatment.
Why it mattersThe peer-reviewed phase 3 findings add evidence for symptom and weight outcomes in a defined population with obesity and knee osteoarthritis. They do not establish disease-modifying effects or long-term benefit-risk beyond the studied follow-up, and the adverse-event imbalance needs to remain visible in clinical and safety interpretation. More on Approvals & regulatory →
- 03
WHO publishes a larger global reference catalogue for tuberculosis drug-resistance mutations
Source: World Health Organization
On November 10, WHO published the third edition of its Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. WHO says the reference now incorporates data from more than 71,000 clinical isolates collected in over 75 countries, with increases of 37% in data volume and 12% in country coverage compared with the 2023 edition. The update expands evidence for newer and repurposed medicines including pretomanid and cycloserine, revises bioinformatic and statistical methods, and adds an enhanced mutation-interpretation framework and practical guidance.
Why it mattersThe catalogue supports more consistent interpretation of genomic and sequencing-based TB drug-susceptibility tests, which can inform laboratory reporting, surveillance and diagnostic development. It is an evidence reference for interpreting mutations, not a standalone treatment guideline or a new drug approval. More on Approvals & regulatory →
- 04
FDA requires GLP-1 medicines to add warnings about a rare optic-nerve condition
Source: U.S. Food and Drug Administration
In a November 9 Drug Safety Communication, the FDA said available evidence indicates a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare optic-nerve blood-flow disorder that can cause sudden, painless vision loss, with GLP-1 receptor agonists. The agency is requiring application holders for all GLP-1 RA medicines to add information to the Warnings and Precautions section of product labelling. The FDA describes a potential risk based on its review; it does not establish that the medicines caused every reported case.
Why it mattersThis is a regulatory labelling action and an important pharmacovigilance update for a widely used drug class. Safety teams and clinicians should distinguish the rare potential event from background risk and review the FDA's evidence, class-wide labelling requirements and reporting guidance. More on Approvals & regulatory →
- 05
FDA issues an early alert for Intersurgical breathing systems after connector failures
Source: U.S. Food and Drug Administration
The FDA listed an early alert on November 10 for specified Intersurgical 22mm Smoothbore breathing tubes and systems. The manufacturer reported that some soft connectors may detach because too little solvent was used to bond them, potentially causing loss or compromise of ventilation. The FDA says affected lots should be stopped, quarantined and returned; it was still collecting information, and the manufacturer had reported no serious injuries or deaths as of November 3.
Why it mattersA connector failure in a breathing circuit can interrupt ventilation and create an immediate patient-safety risk. Hospitals and device-safety teams should identify the exact affected product and lot numbers and follow the FDA and manufacturer notices; this is an early alert, not a final FDA determination. More on Approvals & regulatory →
- 06
FDA flags Arrow guidewire products over possible coating detachment
Source: U.S. Food and Drug Administration
The FDA's November 10 early-alert list includes specified Arrow International guidewires and catheter products containing hydrophilic-coated spring-wire guide components. Teleflex reported that the coating may swell inconsistently in saline, clump and detach, potentially releasing particles into the bloodstream and increasing embolic risk. The FDA advises identifying and quarantining affected devices and returning them; the agency is still reviewing the issue, and the company reported no serious injuries or deaths as of November 5.
Why it mattersThis is a device-quality and potential embolic-safety issue affecting specified product configurations, not every Arrow catheter or guidewire. Clinical engineering, procurement and vascular-access teams should reconcile product identifiers and lots against the FDA notice. More on Approvals & regulatory →
- 07
BioNTech agrees to buy an FDA priority-review voucher for $205 million
Source: U.S. Securities and Exchange Commission filing / BioNTech
BioNTech disclosed on November 10 that it had agreed to acquire a U.S. FDA Priority Review Voucher from Scholar Rock for $205 million in cash. A voucher can shorten the FDA's target review timeline for one application. BioNTech says it intends to use it for a future filing from its late-stage oncology pipeline; the deal remains subject to customary closing conditions, including antitrust clearance.
Why it mattersThe transaction illustrates the commercial value of expedited regulatory review for oncology programmes. A priority-review voucher does not guarantee approval, and the planned filing, regulatory outcome and deal completion remain future events. Not investment advice. More on Approvals & regulatory →
Market news · Not investment advice
- 08
Arbutus says FDA has lifted the clinical hold on its AB-101 investigational cancer drug
Source: Arbutus Biopharma
In a November 10 corporate update, Arbutus said the FDA lifted the 2023 clinical hold on its investigational oral PD-L1 inhibitor AB-101 in October, following a Phase 1 trial conducted abroad. The company said the hold removal allows further U.S. clinical development and that it is evaluating next steps. This is permission to continue development, not marketing approval or evidence of efficacy.
Why it mattersThe update changes the development status of an investigational oncology candidate and may be relevant to future trial planning and company monitoring. The next clinical steps and any evidence of benefit or safety in larger studies are still pending. Not investment advice. More on Approvals & regulatory →
- 09
Capricor submits additional phase 3 extension data while FDA reviews its Duchenne therapy
Source: Capricor Therapeutics
Capricor said on November 10 that its biologics licence application for investigational deramiocel in Duchenne muscular dystrophy remains under FDA review, with a November 22, 2026 target action date. The company reported that a major BLA amendment included two-year open-label extension data from HOPE-3 and proposed an indication focused on upper-limb impairment in patients older than 9 years. In the extension, patients who switched from placebo to deramiocel had 76% slower upper-limb decline than during their prior year on placebo; this was an open-label, cross-phase comparison, not a new randomized comparison.
Why it mattersThe update is relevant to a near-term regulatory review, but deramiocel remains investigational until the FDA decides on the application. The open-label extension result should be interpreted separately from the randomized Phase 3 evidence and alongside the FDA's review of the full application. Not investment advice. More on Approvals & regulatory →
- 10
Phase 3 survodutide trial meets its cardiovascular safety endpoint, sponsor reports
Source: Boehringer Ingelheim
Boehringer Ingelheim reported on November 9 that the Phase 3 SYNCHRONIZE-CVOT trial met its primary cardiovascular safety endpoint for survodutide in adults with overweight or obesity and established cardiovascular disease, chronic kidney disease, or multiple weight-related risk factors. The sponsor reported a hazard ratio of 0.89 (95% CI 0.67–1.18) for five-point major adverse cardiovascular events versus placebo and said the results were presented at the American Heart Association Scientific Sessions and published in The Lancet. These are sponsor-reported trial findings; survodutide remains investigational.
Why it mattersThe result adds cardiovascular outcome data for an investigational dual glucagon/GLP-1 agonist in a high-risk population. It addresses cardiovascular safety in the studied setting, not regulatory approval or proof that the drug prevents cardiovascular events. Clinical interpretation should await the full peer-reviewed report and broader benefit-risk assessment. More on Approvals & regulatory →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
